GSK has walked away from a $2.2 billion biobucks neurodegenerative disease pact with Alector that has seen both drugs ...
The FDA has paused a controversial policy of releasing letters describing its rationale for rejecting drugs, Fierce Biotech ...
Prime Medicine has come out ahead in its patent dispute with fellow gene editing biotech Beam Therapeutics, after a panel of ...
The merged entity will retain the Scipher brand and take advantage of Chemomab’s Nasdaq listing, although the ticker will ...
Satellos Bioscience has shared evidence that its Duchenne muscular dystrophy (DMD) drug candidate is active in adults, ...
AstraZeneca is paying Sino Biopharmaceutical $200 million upfront for ex-China rights to a late-phase challenger to Merck & ...
Boehringer Ingelheim has landed an exclusive license to Prime Vector Technologies’ (PVT) viral vector platform for developing ...
MeiraGTx has secured an investment of up to $400 million from Oberland Capital to help get its late-stage gene therapies | As ...
As U.S. lawmakers continue to scrutinize the consequences of China’s expanding role in biotech innovation, industry insiders ...
Phase 3 trials of Kailera Therapeutics’ oral GLP-1 prospect have hit their primary endpoints, positioning the biotech’s ...
As Novo Nordisk looks for new ways to broaden its semaglutide GLP-1 franchise, the Danish drugmaker has signed a new deal ...
A month after Genentech confirmed the restructuring of its early development group, the Roche subsidiary has now disclosed ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results